These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1781751)

  • 21. High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma.
    Marolleau JP; Baccard M; Flageul B; Rybojad M; Laroche L; Vérola O; Brandely M; Morel P; Gisselbrecht C
    Arch Dermatol; 1995 May; 131(5):574-9. PubMed ID: 7741545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utility of flow cytometry immunophenotyping and DNA ploidy studies for diagnosis and characterization of blood involvement in CD4+ Sézary's syndrome.
    Lima M; Almeida J; dos Anjos Teixeira M; Queiros ML; Santos AH; Fonseca S; Balanzategui A; Justica B; Orfao A
    Haematologica; 2003 Aug; 88(8):874-87. PubMed ID: 12935975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interleukin-7 receptor expression in cutaneous T-cell lymphomas.
    Bagot M; Charue D; Boulland ML; Gaulard P; Revuz J; Schmitt C; Wechsler J
    Br J Dermatol; 1996 Oct; 135(4):572-5. PubMed ID: 8915148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The emergence of Sézary cells during the treatment of cutaneous T-cell lymphoma.
    Sato M; Ishikawa O; Miyachi Y
    Br J Dermatol; 1995 Nov; 133(5):810-3. PubMed ID: 8555042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-grade malignant lymphoma arising from Sézary's syndrome. A case report.
    Kienitz T; Burg G; Schmoeckel C; Weitz H; Braun-Falco O
    Dermatologica; 1979; 158(2):126-36. PubMed ID: 761696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of cutaneous T-cell lymphomas with TP-5. Evaluation of the clinical effect in 8 patients.
    Przybilla B; Burg G; Schmoeckel C; Braun-Falco O
    Acta Derm Venereol; 1983; 63(6):524-9. PubMed ID: 6198843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Profound deficiency in normal circulating T cells in erythrodermic cutaneous T-cell lymphoma.
    Heald P; Yan SL; Edelson R
    Arch Dermatol; 1994 Feb; 130(2):198-203. PubMed ID: 8304758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
    Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
    Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erythrodermic cutaneous T-cell lymphoma: how to differentiate this rare disease from atopic dermatitis.
    Miyagaki T; Sugaya M
    J Dermatol Sci; 2011 Oct; 64(1):1-6. PubMed ID: 21872448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preliminary discussion on the value of (18)F-FDG PET/CT in the diagnosis and early staging of non-mycosis fungoides/Sézary's syndrome cutaneous malignant lymphomas.
    Dan S; Qiang G; Shu-Xia W; Chang-Hong L
    Eur J Radiol; 2015 Jul; 84(7):1293-8. PubMed ID: 25982461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early diagnosis of mycosis fungoides and Sézary's syndrome by morphometric analysis of lymphoid cells in the skin.
    Meijer CJ; van der Loo EM; van Vloten WA; van der Velde EA; Scheffer E; Cornelisse CJ
    Cancer; 1980 Jun; 45(11):2864-71. PubMed ID: 6966534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non lymphoblastic T cell lymphomas with prevalent skin involvement different from mycosis fungoides or Sézary's syndrome. A retrospective study of 6 cases in Europe.
    Grob JJ; Horchowski N; Tubiana N; Gabriel B; Gastaut JA; Hassoun J; Jouve I; Carcassone Y; Bonerandi JJ
    Dermatologica; 1988; 177(2):82-97. PubMed ID: 3262542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD4
    Vonderheid EC; Hou JS
    Leuk Lymphoma; 2018 Feb; 59(2):330-339. PubMed ID: 28595473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum levels of angiopoietin-2, but not angiopoietin-1, are elevated in patients with erythrodermic cutaneous T-cell lymphoma.
    Kawaguchi M; Sugaya M; Suga H; Miyagaki T; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
    Acta Derm Venereol; 2014 Jan; 94(1):9-13. PubMed ID: 23817541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2: basis for therapy of cutaneous T cell lymphoma.
    Zaki MH; Wysocka M; Everetts SE; Wang KS; French LE; Ritz J; Rook AH
    J Invest Dermatol; 2002 Feb; 118(2):366-71. PubMed ID: 11841558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serological immunomarkers in cutaneous T cell lymphoma.
    Hassel JC; Meier R; Joller-Jemelka H; Burg G; Dummer R
    Dermatology; 2004; 209(4):296-300. PubMed ID: 15539892
    [TBL] [Abstract][Full Text] [Related]  

  • 37. C-KIT expression in primary cutaneous T-cell lymphomas.
    Brauns TC; Schultewolter T; Dissemond J; Maschke J; Goos M
    J Cutan Pathol; 2004 Oct; 31(9):577-82. PubMed ID: 15330987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comment on B ratings for erythrodermic cutaneous T-cell lymphoma.
    Vonderheid E
    Eur J Cancer; 2018 Sep; 101():281-283. PubMed ID: 30017384
    [No Abstract]   [Full Text] [Related]  

  • 40. 13-cis-retinoic acid effective in mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group.
    Thomsen K; Molin L; Volden G; Lange Wantzin G; Hellbe L
    Acta Derm Venereol; 1984; 64(6):563-6. PubMed ID: 6084938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.